Table 1 |
|
|
Baseline characteristics of 344 patients with systemic autoimmune diseases treated with biological agents |
|
|
n = 344 |
|
|
|
|
|
Females |
270 (78%) |
|
|
|
|
Mean age (years) |
42.74 ± 0.83 |
|
Mean time of follow up (months) |
26.76 ± 1.14 (0.5-105) |
|
Autoimmune diseases |
|
|
- Systemic lupus erythematosus |
140 (41%) |
|
- Systemic vasculitis |
50 (14%) |
|
- Inflammatory myopathies |
38 (11%) |
|
- Behçet disease |
31 (9%) |
|
- Sjögren syndrome |
23 (7%) |
|
- Other diseases* |
62 (18%) |
|
Previous therapies (ever exposed) |
|
|
- Oral corticosteroids |
332 (97%) |
|
- Methylprednisolone pulses |
86 (25%) |
|
- Immunosuppressants |
282 (82%) |
|
- Intravenous immunoglobulins |
89 (26%) |
|
- Plasma exchange |
10 (3%) |
|
- Other therapies |
109 (32%) |
|
Cumulated dose/length of previous therapies |
|
|
- Mean length of prednisone therapy (years) |
8.04 ± 0.65 |
|
- Cumulated dose of cyclophosphamide (gr) |
7.18 ± 1.11 |
|
- Mean length of mycophenolate (years) |
2.20 ± 0.39 |
|
- Mean length of azathioprine (years) |
1.44 ± 0.35 |
|
- Number of previous immunosuppressants |
|
|
> = 3 |
73 (21%) |
|
> = 4 |
25 (7%) |
|
Biological agent |
|
|
- Rituximab |
264 (77%) |
|
- Infliximab |
37 (11%) |
|
- Etanercept |
21 (6%) |
|
- Adalimumab |
19 (5%) |
|
- Other |
3 (1%) |
|
Therapies administered concomitantly |
|
|
- Oral corticosteroids |
312 (91%) |
|
- Immunosuppressants |
193 (56%) |
|
- Intravenous immunoglobulins |
14 (4%) |
|
- Plasma exchange |
11 (3%) |
|
Time of exposure to biological (person-years) |
|
|
- Total time |
495 |
|
- Exposure to rituximab |
328 |
|
- Exposure to infliximab |
52 |
|
- Exposure to etanercept |
66 |
|
- Exposure to adalimumab |
30 |
|
Retreatment |
55 (16%) |
|
Switch |
33 (10%) |
|
|
|
|
See the complete list of diseases included in the Methods section. |
|
|
Díaz-Lagares et al. Arthritis Research & Therapy 2011 13:R112 doi:10.1186/ar3397 |
|
